TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS

OBJECTIVES: To determine when re-censoring should be incorporated in statistical analyses undertaken to adjust for treatment switching in randomised controlled trials, and to demonstrate the utility of inverse probability weighting (IPW) as an alternative to re-censoring. Treatment switching often h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2017-05, Vol.20 (5), p.A314
Hauptverfasser: Latimer, N, Abrams, KR
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page A314
container_title Value in health
container_volume 20
creator Latimer, N
Abrams, KR
description OBJECTIVES: To determine when re-censoring should be incorporated in statistical analyses undertaken to adjust for treatment switching in randomised controlled trials, and to demonstrate the utility of inverse probability weighting (IPW) as an alternative to re-censoring. Treatment switching often has a crucial impact on estimates of the effectiveness and cost-effectiveness of new oncology treatments. Switching adjustment methods such as rank preserving structural failure time models (RPSFTM) and two-stage estimation estimate 'counterfactual' (i.e. in the absence of switching) survival times and incorporate re-censoring to guard against informative censoring in the counterfactual dataset. However, re-censoring often involves a loss of longer term survival information which is problematic when estimates of long-term survival effects are required. METHODS: A simulation study was conducted, testing RPSFTM and two-stage adjustment methods with and without re-censoring, and with IPW in place of re-censoring, across scenarios with various switch proportions and sizes and time dependencies of the treatment effect. Methods were assessed according to their estimation of true restricted mean survival (in the absence of switching) at the end of trial follow-up. RESULTS: RPSFTM analyses that incorporated re-censoring were prone to bias when the treatment effect decreased over time - over-estimating the treatment effect by approximately 3-11% in these scenarios, compared to bias of approximately 0-2% for RPSFTM and two-stage analyses that did not incorporate re-censoring. Two-stage analyses usually over-estimated the treatment effect when re-censoring was incorporated and consistently under-estimated the treatment effect when re-censoring was not incorporated. Using IPW in place of re-censoring resulted in low levels of bias when the censoring proportion and switching proportion were relatively low (both approximately 25%). CONCLUSIONS: Re-censoring should not always be incorporated in adjustment analyses when the objective is to estimate the long-term treatment effect. Conducting analyses with and without re-censoring may provide useful information on the size of the true treatment effect.
doi_str_mv 10.1016/j.jval.2017.05.005
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2097660765</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2097660765</sourcerecordid><originalsourceid>FETCH-proquest_journals_20976607653</originalsourceid><addsrcrecordid>eNqNjbFOwzAQhi0EEqXwAkwnsZJwTuqEslmOS4xSu9hXVUxVhzJEFYWG8kp9TRxgYev0n777_jvGrjmmHHlx16bt12qTZsjLFEWKKE7YgItslIzKPD-NM47vkxy5OGcXXdciYpFnYsAO5MDrRGkbnL8F58E6gv-QaklgQkwNz3MdyDj7AMobMko2oJwNptJe9jzAotYW5GzWvBj7CIEiDr_iVFPtqtBfl9XTPBBM4j_yWtJUW4KwMKTqvmUsqMbYnxZ5I5twyc5eV5tuffWXQ3Yz0dFO3nfbj_26-1y22_3uLa6WGY7LosCyEPlx1jcvvVZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2097660765</pqid></control><display><type>article</type><title>TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS</title><source>Elsevier ScienceDirect Journals Complete</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Latimer, N ; Abrams, KR</creator><creatorcontrib>Latimer, N ; Abrams, KR</creatorcontrib><description>OBJECTIVES: To determine when re-censoring should be incorporated in statistical analyses undertaken to adjust for treatment switching in randomised controlled trials, and to demonstrate the utility of inverse probability weighting (IPW) as an alternative to re-censoring. Treatment switching often has a crucial impact on estimates of the effectiveness and cost-effectiveness of new oncology treatments. Switching adjustment methods such as rank preserving structural failure time models (RPSFTM) and two-stage estimation estimate 'counterfactual' (i.e. in the absence of switching) survival times and incorporate re-censoring to guard against informative censoring in the counterfactual dataset. However, re-censoring often involves a loss of longer term survival information which is problematic when estimates of long-term survival effects are required. METHODS: A simulation study was conducted, testing RPSFTM and two-stage adjustment methods with and without re-censoring, and with IPW in place of re-censoring, across scenarios with various switch proportions and sizes and time dependencies of the treatment effect. Methods were assessed according to their estimation of true restricted mean survival (in the absence of switching) at the end of trial follow-up. RESULTS: RPSFTM analyses that incorporated re-censoring were prone to bias when the treatment effect decreased over time - over-estimating the treatment effect by approximately 3-11% in these scenarios, compared to bias of approximately 0-2% for RPSFTM and two-stage analyses that did not incorporate re-censoring. Two-stage analyses usually over-estimated the treatment effect when re-censoring was incorporated and consistently under-estimated the treatment effect when re-censoring was not incorporated. Using IPW in place of re-censoring resulted in low levels of bias when the censoring proportion and switching proportion were relatively low (both approximately 25%). CONCLUSIONS: Re-censoring should not always be incorporated in adjustment analyses when the objective is to estimate the long-term treatment effect. Conducting analyses with and without re-censoring may provide useful information on the size of the true treatment effect.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2017.05.005</identifier><language>eng</language><publisher>Lawrenceville: Elsevier Science Ltd</publisher><subject>Adjustment ; Analysis ; Bias ; Censorship ; Clinical research ; Clinical trials ; Cost analysis ; Counterfactual thinking ; Long term ; Oncology ; Prone ; Simulation ; Statistical analysis ; Statistics ; Survival ; Weighting</subject><ispartof>Value in health, 2017-05, Vol.20 (5), p.A314</ispartof><rights>Copyright Elsevier Science Ltd. May 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930,31004</link.rule.ids></links><search><creatorcontrib>Latimer, N</creatorcontrib><creatorcontrib>Abrams, KR</creatorcontrib><title>TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS</title><title>Value in health</title><description>OBJECTIVES: To determine when re-censoring should be incorporated in statistical analyses undertaken to adjust for treatment switching in randomised controlled trials, and to demonstrate the utility of inverse probability weighting (IPW) as an alternative to re-censoring. Treatment switching often has a crucial impact on estimates of the effectiveness and cost-effectiveness of new oncology treatments. Switching adjustment methods such as rank preserving structural failure time models (RPSFTM) and two-stage estimation estimate 'counterfactual' (i.e. in the absence of switching) survival times and incorporate re-censoring to guard against informative censoring in the counterfactual dataset. However, re-censoring often involves a loss of longer term survival information which is problematic when estimates of long-term survival effects are required. METHODS: A simulation study was conducted, testing RPSFTM and two-stage adjustment methods with and without re-censoring, and with IPW in place of re-censoring, across scenarios with various switch proportions and sizes and time dependencies of the treatment effect. Methods were assessed according to their estimation of true restricted mean survival (in the absence of switching) at the end of trial follow-up. RESULTS: RPSFTM analyses that incorporated re-censoring were prone to bias when the treatment effect decreased over time - over-estimating the treatment effect by approximately 3-11% in these scenarios, compared to bias of approximately 0-2% for RPSFTM and two-stage analyses that did not incorporate re-censoring. Two-stage analyses usually over-estimated the treatment effect when re-censoring was incorporated and consistently under-estimated the treatment effect when re-censoring was not incorporated. Using IPW in place of re-censoring resulted in low levels of bias when the censoring proportion and switching proportion were relatively low (both approximately 25%). CONCLUSIONS: Re-censoring should not always be incorporated in adjustment analyses when the objective is to estimate the long-term treatment effect. Conducting analyses with and without re-censoring may provide useful information on the size of the true treatment effect.</description><subject>Adjustment</subject><subject>Analysis</subject><subject>Bias</subject><subject>Censorship</subject><subject>Clinical research</subject><subject>Clinical trials</subject><subject>Cost analysis</subject><subject>Counterfactual thinking</subject><subject>Long term</subject><subject>Oncology</subject><subject>Prone</subject><subject>Simulation</subject><subject>Statistical analysis</subject><subject>Statistics</subject><subject>Survival</subject><subject>Weighting</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqNjbFOwzAQhi0EEqXwAkwnsZJwTuqEslmOS4xSu9hXVUxVhzJEFYWG8kp9TRxgYev0n777_jvGrjmmHHlx16bt12qTZsjLFEWKKE7YgItslIzKPD-NM47vkxy5OGcXXdciYpFnYsAO5MDrRGkbnL8F58E6gv-QaklgQkwNz3MdyDj7AMobMko2oJwNptJe9jzAotYW5GzWvBj7CIEiDr_iVFPtqtBfl9XTPBBM4j_yWtJUW4KwMKTqvmUsqMbYnxZ5I5twyc5eV5tuffWXQ3Yz0dFO3nfbj_26-1y22_3uLa6WGY7LosCyEPlx1jcvvVZA</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Latimer, N</creator><creator>Abrams, KR</creator><general>Elsevier Science Ltd</general><scope>7QJ</scope></search><sort><creationdate>20170501</creationdate><title>TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS</title><author>Latimer, N ; Abrams, KR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_20976607653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adjustment</topic><topic>Analysis</topic><topic>Bias</topic><topic>Censorship</topic><topic>Clinical research</topic><topic>Clinical trials</topic><topic>Cost analysis</topic><topic>Counterfactual thinking</topic><topic>Long term</topic><topic>Oncology</topic><topic>Prone</topic><topic>Simulation</topic><topic>Statistical analysis</topic><topic>Statistics</topic><topic>Survival</topic><topic>Weighting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Latimer, N</creatorcontrib><creatorcontrib>Abrams, KR</creatorcontrib><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Latimer, N</au><au>Abrams, KR</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS</atitle><jtitle>Value in health</jtitle><date>2017-05-01</date><risdate>2017</risdate><volume>20</volume><issue>5</issue><spage>A314</spage><pages>A314-</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>OBJECTIVES: To determine when re-censoring should be incorporated in statistical analyses undertaken to adjust for treatment switching in randomised controlled trials, and to demonstrate the utility of inverse probability weighting (IPW) as an alternative to re-censoring. Treatment switching often has a crucial impact on estimates of the effectiveness and cost-effectiveness of new oncology treatments. Switching adjustment methods such as rank preserving structural failure time models (RPSFTM) and two-stage estimation estimate 'counterfactual' (i.e. in the absence of switching) survival times and incorporate re-censoring to guard against informative censoring in the counterfactual dataset. However, re-censoring often involves a loss of longer term survival information which is problematic when estimates of long-term survival effects are required. METHODS: A simulation study was conducted, testing RPSFTM and two-stage adjustment methods with and without re-censoring, and with IPW in place of re-censoring, across scenarios with various switch proportions and sizes and time dependencies of the treatment effect. Methods were assessed according to their estimation of true restricted mean survival (in the absence of switching) at the end of trial follow-up. RESULTS: RPSFTM analyses that incorporated re-censoring were prone to bias when the treatment effect decreased over time - over-estimating the treatment effect by approximately 3-11% in these scenarios, compared to bias of approximately 0-2% for RPSFTM and two-stage analyses that did not incorporate re-censoring. Two-stage analyses usually over-estimated the treatment effect when re-censoring was incorporated and consistently under-estimated the treatment effect when re-censoring was not incorporated. Using IPW in place of re-censoring resulted in low levels of bias when the censoring proportion and switching proportion were relatively low (both approximately 25%). CONCLUSIONS: Re-censoring should not always be incorporated in adjustment analyses when the objective is to estimate the long-term treatment effect. Conducting analyses with and without re-censoring may provide useful information on the size of the true treatment effect.</abstract><cop>Lawrenceville</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/j.jval.2017.05.005</doi></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2017-05, Vol.20 (5), p.A314
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_journals_2097660765
source Elsevier ScienceDirect Journals Complete; Applied Social Sciences Index & Abstracts (ASSIA); EZB-FREE-00999 freely available EZB journals
subjects Adjustment
Analysis
Bias
Censorship
Clinical research
Clinical trials
Cost analysis
Counterfactual thinking
Long term
Oncology
Prone
Simulation
Statistical analysis
Statistics
Survival
Weighting
title TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T03%3A33%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TO%20RE-CENSOR,%20OR%20NOT%20TO%20RE-CENSOR,%20THAT%20IS%20THE%20QUESTION:%20CRITICAL%20CONSIDERATIONS%20WHEN%20APPLYING%20STATISTICAL%20METHODS%20TO%20ADJUST%20FOR%20TREATMENT%20SWITCHING%20IN%20CLINICAL%20TRIALS&rft.jtitle=Value%20in%20health&rft.au=Latimer,%20N&rft.date=2017-05-01&rft.volume=20&rft.issue=5&rft.spage=A314&rft.pages=A314-&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2017.05.005&rft_dat=%3Cproquest%3E2097660765%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2097660765&rft_id=info:pmid/&rfr_iscdi=true